Podcast - Assessing the State of Healthcare Restructurings
Leaders in Law: Life Sciences and Technology Transactions with Jekkie Kim
Health-e Law Podcast, Episode 22 | J.P. Morgan Healthcare 2026 and Beyond: Regulation, Technology and the Future of Health Equity
Podcast — Spotlight on US State Healthcare Transaction Review Laws
Taking the Pulse: A Health Care and Life Sciences Video Podcast | Episode 268: Inside South Carolina’s Life Sciences Growth with James Chappell of SCbio
JONES DAY TALKS®: The CNPV Pilot Program: FDA's High-Speed Lane for Drug Approval
Hospice Insights Podcast - Endings and Beginnings: Reflections on Meg Pekarske’s 25+ Years as a Hospice Advocate
Health-e Law Podcast, Episode 21 | J.P. Morgan Healthcare 2026 and Beyond: Technology Adoption and Strategic Transformation Under Cost Pressure
Got an Audit Letter? Here’s What Every Health Care Provider Should Do
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 267: Leading Legal Strategy at a Growing Health System with Kelli Ferry of Novant Health
We get AI for work™: Preparing Real-World Healthcare Environments for an AI-Driven Future
Health-e Law Podcast, Episode 20 | J.P. Morgan Healthcare 2026 and Beyond: How Digital Innovation Shapes Healthcare M&A
Podcast - Minority Deals in Healthcare Private Equity: An Evolving Opportunity for GPs and Founders Counsel That Cares Podcast Series
Pay Transparency + the Power of Preventive Strategies: Episode 3 — Pivoting Toward Preparation in the Life Sciences
Pay Transparency + the Power of Preventive Strategies: Episode 2 — Healthcare Compliance Crossroads
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 266: Navigating Today’s Healthcare Landscape with Leighton Roper of Maynard Nexsen
Hospice Insights Podcast - Reimagining How We Navigate Change and Loss: A Conversation with Sonya Dolan and Bridget Sumser of Mettle Health
Podcast - The Fast-Growing Wound Care Industry
Concierge Practices: Getting Started and Staying Compliant
Podcast - J.P. Morgan Healthcare Conference Recap: What Dealmakers Expect in 2026
On March 5, 2026, the U.S. Department of Health and Human Services (HHS) Office for Civil Rights (OCR) announced a settlement with MMG Fusion, LLC (MMG). MMG is a Maryland software company that was the subject of a complaint...more
Key Takeaways - The Missouri AG filed suit in St. Louis County Circuit Court against several PBMs and drug manufacturers, alleging they conspired to manipulate Missouri’s health care market and unlawfully drive up insulin...more
Our FDA: Drug & Device Team explores the Food and Drug Administration’s updated draft guidance that eases biosimilar development by allowing greater use of non-U.S.-licensed comparator products in clinical studies....more
Losing a loved one to the negligence of another person is devastating, but insult is added to injury when you begin to receive expensive bills for medical expenses, the funeral and the burial. This is only the beginning...more
In Fish & Richardson’s 2025 biologics and biosimilars review, we cover Food and Drug Administration (FDA) approvals, new biosimilar launches, Biologics Price Competition and Innovation Act (BPCIA) litigation and other...more
For years, the commercial compounding and telehealth industry blossomed, buoyed by exploding consumer interest in GLP-1s and other compounded drugs. But things are changing. We recently blogged more generally about the...more
New Jersey advanced practice nurses (“APNs”) and physician assistants (“PAs”) have until April 2, 2026, to secure collaborating or supervising physicians before pandemic-era practice waivers expire. Healthcare practices and...more
The Centers for Medicare and Medicaid Services (“CMS”) recently announced new healthcare fraud measures that include the imposition of a six-month moratorium on provider enrollments of new durable medical equipment,...more
On March 3, 2026, the U.S. District Court for the District of Columbia issued a significant decision for hospitals participating in the federal 340B Drug Pricing Program. In Albany Med Health System v. Health Resources and...more
The MHRA is seeking input on three proposed approaches to recognising the EU CE mark for medical devices in the UK....more
As we approach the warmer months ahead, heat illness prevention remains a top priority for regulators at both the federal and state levels. Most recently, the Virginia House of Delegates and Senate have introduced companion...more
FDA recently published a new draft Guidance for Industry titled “New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug Products: Questions and Answers” (Mar. 2026) (the “Draft Guidance”). The Draft Guidance...more
CMS has released the payment amounts and performance targets for its new voluntary ACCESS model – a condition-based, outcomes-driven payment approach that could reshape how chronic care is delivered in Original Medicare....more
It will likely be a slow healthcare week in Washington, DC. The House is out of session this week, and while the Senate is in session, most of its attention will be on immigration-related hearings, pending nominations, and...more
On March 3, 2026, a federal district court in Minnesota dismissed a lawsuit alleging that an employer imprudently managed its self-funded health plan’s prescription drug benefit, causing the plan participants to overpay for...more
On February 23, 2026, Cody Matthew Herche, the head of the Department of Justice’s (DOJ) Trade Fraud Task Force created six months ago, announced that the U.S. Attorney’s Office for the Northern District of Illinois will...more
In fiscal year 2024, approximately 8,492 H-1B visas were approved for workers in medicine and health occupations. The American Medical Association and over 50 national specialty societies and state medical associations...more
Sheppard’s Digital Health & Innovation Team attended the 2026 ViVE Conference in Los Angeles where healthcare innovation was on full display. Health systems, payers, and healthcare technology leaders were discussing the...more
Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....more
The U.S. Supreme Court will decide what constitutes “induced infringement” where the generic manufacturer makes statements outside approved labeling that carves out a patented use....more
A recent advisory opinion from the U.S. Department of Health and Human Services Office of Inspector General (OIG) may give manufacturers more daylight to structure bundled discounts under the Discount Safe Harbor (DSH) to the...more
The Texas Medical Board has published proposed regulations that will fundamentally reshape how ketamine therapy clinics operate in Texas. Published in the January 2, 2026 Texas Register, these new rules under Chapter 173,...more
When Congress enacted the Modernization of Cosmetics Regulation Act in 2022, MoCRA was hailed as a sweeping overhaul of the Food and Drug Administration’s cosmetic safety and quality standards. Yet, years later, MoCRA has...more
In a previous posting, we flagged how the BIOSECURE Act (enacted as Section 851 of the Fiscal Year 2026 National Defense Authorization Act) reflects a growing focus on biotechnology supply chains within federal procurement....more
Enacted 25 years ago, the federal New Markets Tax Credit (NMTC) Program has become a powerful financing tool for health care organizations. Beyond simply offering tax credits to investors, the NMTC Program can provide health...more